BSE & NSE
27 Jul - 29 Jul '21
₹695 - ₹720
Glenmark Life Sciences is an Indian producer of drugs that supplies APIs to a number of pharmaceutical companies globally. It is associated with 16 of the largest 20 generic drug companies worldwide. In all, it supplies materials to 540 pharma companies all over the world. The company works to positively impact all aspects of the value chain and support customers in regions such as North America, Europe, Japan, Latin America and ROW with product identification and development apart from R&D, manufacturing and delivery.
During the Glenmark Life Sciences IPO, its shares were listed at a 4 per cent premium over the issue price of Rs 720 per share. The company raised Rs 1,060 crore through the fresh issue and Rs 453.60 crore from offer for sale. It was subscribed 44.17 times. As the 30-day lock-in period for investors ended, the stock traded below the IPO issue price of Rs 720.
Glenmark Life Sciences has accounted for 30-35% of Glenmark Pharma's overall value. Glenmark Pharma itself has been listed on the exchanges for more than 20 years and is widely considered to be delivering strong returns.
The API segment is expected to grow at a CAGR of 8.5% in the next five years. Moreover, Glenmark Life Sciences has a number of blue-chip clients as it is associated with 16 out of the 20 largest generic drug manufacturers.
The company has built technically complex and niche molecules in a business characterised by high volumes and low margins, It has more than 30 per cent market share in some of its principal products which combine to contribute 44 per cent to the total business. Its total market size is $142 billion with 403 Drug Master Files (DMFs) and 39 (owned and co-owned) patents.
It is routinely subjected to inspections from regulators and any adverse observations could
There is terrific scope to expand on account of Glenmark Life Sciences' strong cash flow. Its robust R&D infrastructure would ensure that it can improve the quality of products and gain more customers.
Threats:In the event that the company fails to make the right predictions for the demand of its products, it could become difficult to manage inventory.
You can apply for the Glenmark Life Sciences Ltd. IPO in these ways:
Link your personal bank A/C to a trusted UPI ID and map it with your TradeSmart account. Now, proceed further to book your IPO. On acceptance of the mandate, the bid amount will get blocked in your bank account Learn more.
1. If you are an Existing TradeSmart demat account holder and wish to apply for an Glenmark Life Sciences Ltd. click here.
2. If you don't have a TradeSmart Account? Sign up.
What is the date of listing for Glenmark Life Sciences IPO?
The Glenmark Life Sciences IPO date is August 6, 2021.
Which categories of investors are allowed to participate in Glenmark Life Sciences IPO?
Retails investors, qualified institutional buyers and non-institutional investors can participate in Glenmark Life Sciences IPO.
How many Glenmark Life Sciences IPO shares can qualified institutional buyers subscribe to?
The company has reserved 50% of the issue is for its qualified institutional buyers.
Who are the bankers for the Glenmark Life Sciences IPO?
BoB Caps, Bank of America Securities, DAM Capital, Goldman Sachs, SBI Capital Markets and Kotak Mahindra Capital are the merchant bankers for this IPO.
What is the minimum order quantity for Glenmark Life Sciences IPO?
The minimum order quantity of Glenmark Life Sciences IPO is 20 shares.